WEBINAR 1: Demystifying Alzheimer’s Blood Biomarkers:
What Every Clinician Needs to Know
Live Event: Tuesday, December 9, 2025 | 1:00 pm – 2:00 pm EST
P.A.C.E.® Credit available until June 9, 2026 | Florida Lab Credit available
WEBINAR 2: Alzheimer's Disease Blood Testing in Clinical Practice:
How to Order, Interpret, and Act on Results
Live Event: Thursday, April 16, 2026 | 1:00 pm – 2:00 pm EST
P.A.C.E.® Credit available until October 16, 2026 | Florida Lab Credit available
This foundational webinar will clarify the science and clinical role of blood-based biomarkers (BBMs) in Alzheimer’s disease (AD). Analytical and clinical performance of AD BBM tests and appropriate positioning of testing within recommended diagnostic pathways alongside cognitive assessment, rule-out labs, and other testing modalities (PET/CSF) will be discussed. Special emphasis will be placed on interpreting positive, indeterminate, and negative test results. Included is a case-based dialogue to address common myths, patient communication tips, and how BBMs enable earlier access to specialist care and potential disease-modifying therapies.
Objectives:
Differentiate AD BBM tests and key performance characteristics for amyloid pathology detection.
Identify appropriate clinical use scenarios to order AD BBM tests within a structured diagnostic workup.
Compare AD BBM tests to PET and CSF for amyloid/tau confirmation.
Interpret positive, negative and indeterminate test results to guide patient management and patient/caregiver consultations.
WEBINAR 3: Implementing AD Blood Testing:
Reimbursement, Cost, and Clinical Workflow
Live Event: TBA
P.A.C.E.® Credit and Florida Lab Credit available
During this fireside chat, experts will examine the practical integration of AD blood-based biomarkers into the healthcare system through a financial, logistical, and workflow lens. Insights on the current coverage landscape, economic value and potential societal impact will be discussed. Considerations for implementing and supporting AD biomarker testing in clinical laboratories will also be shared. The session will conclude with a case study presentation of a system-level analysis of successful biomarker adoption.
Objectives:
Summarize the payer coverage landscape across payer types.
Discuss the integration of testing, ordering logistics, turnaround times and reporting results.
Describe the economic and operational value of AD biomarkers on the healthcare system and patients.
Restate a system-level case study where AD biomarkers were successfully adopted.
David Greeley, MD
Founder and Practicing Neurologist, Northwest Neurological, PLLC
Clinical Associate Professor, Neurology, University of Washington School of Medicine
Zivjena Vucetic, MD, PhD
Adjunct Assistant Professor
College of Science & Technology
Department of Biology, Temple University
Jeffrey Burns, MD, MS
Co-Director, KU Alzheimer’s Disease Research Center, SOM-Kansas City
Division Director, Neurocognitive Division, SOM-Kansas City, Neurology
Jennifer Woodward, MD, MPH
Associate Professor, Family Medicine and Community Health, KU Medical Center
Vice Chair, Clinical Services, Family Medicine and Community Health, The University of Kansas Health System
Medical Director, Ambulatory Operations and Population Health Informatics, The University of Kansas Health System
Medical Director, Quality and Performance Measurement, American Academy of Family Physicians
Jill Morris, PhD
Associate Professor, Neurology, KU Medical Center
Co-Director, KU Alzheimer’s Disease Research Center Biomarker Core
Director, KU Alzheimer’s Disease Center Developmental Projects Program
Speakers TBA
These educational programs are made possible through the generous support of Fujirebio.
Continuing education credits available for up to 6 months from recording:
One P.A.C.E.® credit-hour will be provided for this complimentary basic level program. Fujirebio is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.
This program is approved for 1 Florida Laboratory CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563
Certificate of Attendance is available for all attendees.
To learn about Fujirebio’s high-quality biomarkers for Alzheimer's disease assessment such as the FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio and Lumipulse® G β-Amyloid Ratio (1-42/1-40) CSF tests, please visit https://www.fujirebio.com/en-us/Alzheimer.
This foundational webinar will clarify the science and clinical role of blood-based biomarkers (BBMs) in Alzheimer’s disease (AD). Analytical and clinical performance of AD BBM tests and appropriate positioning of testing within recommended diagnostic pathways alongside cognitive assessment, rule-out labs, and other testing modalities (PET/CSF) will be discussed. Special emphasis will be placed on interpreting positive, indeterminate, and negative test results. Included is a case-based dialogue to address common myths, patient communication tips, and how BBMs enable earlier access to specialist care and potential disease-modifying therapies.
Objectives:
Differentiate AD BBM tests and key performance characteristics for amyloid pathology detection.
Identify appropriate clinical use scenarios to order AD BBM tests within a structured diagnostic workup.
Compare AD BBM tests to PET and CSF for amyloid/tau confirmation.
Interpret positive, negative and indeterminate test results to guide patient management and patient/caregiver consultations.